Skip to main content
. 2022 Aug 24;6(10):2950–2963. doi: 10.1002/hep4.2055

FIGURE 4.

FIGURE 4

DNAJB1‐PKAc‐ph‐S675‐β‐catenin pathway activates expression of CEGR/ALCD‐containing genes in patients with FLC. (A) Immunostaining of the same areas of the liver with antibodies to ph‐S675‐β‐catenin and PGAP1. Arrows show co‐localizations of staining. (B) Western blotting shows an increase of expression of post GPI attachment to proteins 1 (PGAP1), HACE1, and RUNDC1 in tumor sections of patients with FLC. (C) Western blotting shows expression of the components of ph‐S675‐β‐catenin‐TCF4‐p300 complexes. (D) Co‐IP studies. ph‐S675‐β‐catenin was immunoprecipitated, and PKAc, TCF4, p300, and ph‐S675‐β‐catenin were detected by western blot. € Pull‐down assay. Cytoplasmic and nuclear extracts from FLC samples were incubated with streptavidin‐linked TCF4 oligomer, and the interacting proteins were examined by western blot. β‐actin is a negative control. (F) ChIP assay with CEGRs/ALCDs from three oncogenes shown on the left.